TIMP (tissue inhibitors of metalloproteinases), as an important regulatory factor for MMP hydrolysis or activation, also participates in the development and progression of multiple myeloma and the formation of bone disease. This evidence concerns the gene TIMP1 and plasma cell myeloma.